Skin Score Beats Blood Test for Gauging Severity of Childhood Mastocytosis, Study Finds

Pediatric cutaneous mastocytosis is one of those rare diseases that most parents have never heard of until a strange, freckle-like rash appears on their child’s skin and refuses to fade. The condition arises when mast cells, the immune cells best known for triggering allergic reactions, accumulate abnormally in the skin. While the childhood form of the disease usually follows a benign course and often improves with age, doctors have long lacked reliable tools to measure just how severe one child’s disease is compared with another’s. A new observational study from Istanbul Medeniyet University, published in the Archives of Dermatological Research, now offers a data-driven answer, and it challenges a common assumption about a routine blood test.

The research team, led by Leman Tuba Karakurt and colleagues in the Division of Pediatric Allergy and Immunology, retrospectively analyzed 58 children diagnosed with pediatric cutaneous mastocytosis at a single center. Nearly two-thirds of the patients, 63.8 percent, were male. The investigators catalogued each child’s demographic details, clinical subtype, lesion characteristics, allergic comorbidities, history of anaphylaxis, and treatments. They then applied a standardized severity metric, the SCORMA index, which was developed specifically to score the extent and intensity of cutaneous mastocytosis, and measured basal serum tryptase concentrations, a blood marker often used as a proxy for the body’s total mast cell burden.

The first striking finding concerned the distribution of disease subtypes. Maculopapular cutaneous mastocytosis, characterized by scattered spots or plaques that can develop hives when rubbed, dominated the cohort at 58.6 percent of patients. Solitary mastocytomas, raised nodules packed with mast cells, accounted for 15.5 percent, while the rare and potentially more troublesome diffuse cutaneous mastocytosis, in which mast cells infiltrate the skin broadly rather than in discrete patches, made up 13.8 percent. This hierarchy echoes the pattern reported in large international pediatric series and confirms that the diffuse form, though uncommon, remains a clinically important minority that behaves differently from its patchy counterparts.

When the researchers compared SCORMA scores across subtypes, the differences were meaningful. The median SCORMA score for the whole cohort was 25.5, with an interquartile range of 17.8 to 41.4, revealing considerable heterogeneity in how heavily the skin was involved from child to child. Children with diffuse cutaneous mastocytosis scored substantially higher than the rest, with a median of 50.1 versus 24.4 in the other subtypes, a difference that reached statistical significance. In practical terms, the subtype a child carries, above all the diffuse form, is the primary determinant of how severe the skin disease becomes. This supports the idea that clinicians can stratify risk at the moment of diagnosis simply by recognizing the morphological pattern in front of them.

Perhaps the most consequential result of the study, however, concerns the shape of the lesions rather than the subtype label. The team distinguished monomorphic lesions, which look uniformly similar to one another, from polymorphic lesions, which vary in size and appearance. Children with polymorphic lesions had a median SCORMA score of 37.4, compared with just 21.0 among those with monomorphic lesions, a gap so large that the p-value fell below 0.001. This finding aligns with accumulating evidence from histopathological work showing that the two lesion patterns reflect genuinely different biology, and it suggests that lesion polymorphism could serve as a quick visual cue for clinicians estimating disease burden in the clinic without waiting for any laboratory result.

The blood test fared less well. Basal serum tryptase, an enzyme released by mast cells that allergologists frequently measure to gauge mast cell load, was elevated in only 5.2 percent of the entire cohort. Even within the diffuse cutaneous subgroup, the highest-risk patients, elevations appeared in just 37.5 percent, a trend that did not reach statistical significance. In other words, a normal tryptase level did not rule out extensive skin involvement, and most children with significant disease had entirely unremarkable laboratory values. The correlation analysis between SCORMA scores and tryptase concentrations failed to demonstrate a reliable relationship, reinforcing the paper’s central message: for children with cutaneous mastocytosis, standardized clinical scoring such as SCORMA deserves a central place in assessment and follow-up, while tryptase alone should not be trusted to reflect severity.

The study also mapped the allergic landscape surrounding these children, and the results are a reminder that mastocytosis rarely travels alone. Allergic rhinitis affected 20.7 percent of patients, asthma 15.5 percent, and atopic dermatitis 8.6 percent. True anaphylaxis, the feared systemic allergic reaction that mast cell disorders can predispose patients to, was rare in this cohort, documented in only 3.4 percent of children. The relatively low anaphylaxis rate is consistent with the generally benign reputation of pediatric cutaneous mastocytosis, but the burden of atopic comorbidity suggests that children with these unusual skin findings should be evaluated for common allergic diseases as well, since managing one can influence the comfort and quality of life of the other.

Treatment practices in the cohort revealed an interesting tension between precaution and prevalence. Although anaphylaxis was documented in only a small fraction of patients, the majority of children, 56.9 percent, were prescribed an adrenaline auto-injector. This is not necessarily an inconsistency; international guidance, including the World Allergy Organization anaphylaxis recommendations, emphasizes that patients with mast cell disorders can experience sudden, unprovoked mast cell activation, and the consequences of an untreated reaction in a young child are severe enough that clinicians often err on the side of prescribing. Still, the mismatch between a 3.4 percent anaphylaxis rate and a nearly 57 percent auto-injector prescription rate illustrates how uncertainty about risk stratification in this rare disease currently pushes practice toward conservatism.

For the broader field, the study contributes to a growing consensus about how pediatric mastocytosis should be monitored. Prior work from large reference centers has shown that childhood-onset disease with extensive maculopapular lesions often runs a favorable course, and that serum tryptase is far more informative in adult systemic mastocytosis than in the pediatric cutaneous form. The Istanbul data extend this picture by quantifying, within a single well-characterized cohort, how much of the severity story is told by the clinical subtype and lesion morphology themselves. The authors’ conclusion that clinical subtype, particularly diffuse cutaneous mastocytosis, is the primary determinant of skin severity gives clinicians a practical hierarchy: look at the skin first, score it systematically, and treat the tryptase value as supplementary context rather than a verdict.

There are, of course, limits to what a retrospective, single-center study of 58 patients can establish, and the authors are appropriately careful in their claims. The subgroup of diffuse cutaneous mastocytosis patients was small, which is why some comparisons, such as the tryptase elevation rate within that group, produced trends without reaching conventional statistical significance. Longitudinal follow-up will be needed to determine whether high SCORMA scores in early childhood predict slower resolution or greater systemic risk over time. Even so, the study’s practical implications are immediate. For pediatricians and dermatologists confronting a child with mysterious skin lesions, the findings argue for recognizing the subtype, applying a validated severity score, screening for atopic comorbidities, and reserving tryptase for targeted questions rather than treating it as a universal severity meter. In a disease where the skin tells most of the story, the message of this research is refreshingly simple: trust what you can see, measure it consistently, and let the clinical picture, not a single blood value, guide the care of these children.

Subject of Research: Clinical characteristics, serum tryptase levels, and treatment of pediatric cutaneous mastocytosis

Article Title: The evaluation of clinical findings, laboratory profile, and treatment approaches in pediatric cutaneous mastocytosis

Article References: Karakurt, L. T., Çevik, S., Yağmur Altınkaynak, P., Kacar, D., & Arga, M. (2026). The evaluation of clinical findings, laboratory profile, and treatment approaches in pediatric cutaneous mastocytosis. Archives of Dermatological Research, 318(1), Article 405. https://doi.org/10.1007/s00403-026-04885-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04885-0

Keywords: pediatric cutaneous mastocytosis, SCORMA, serum tryptase, diffuse cutaneous mastocytosis, mastocytoma, anaphylaxis, allergic comorbidities, adrenaline auto-injector, mast cells, dermatology, children, disease severity